Published in Am J Respir Crit Care Med on February 12, 2004
New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med (2011) 3.46
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother (2007) 2.58
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc (2006) 1.94
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med (2006) 1.55
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med (2009) 1.16
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother (2012) 0.98
Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother (2010) 0.97
New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res (2010) 0.92
Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob Agents Chemother (2005) 0.89
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother (2014) 0.85
Rifapentine for the treatment of tuberculosis: is it all it can be? Am J Respir Crit Care Med (2004) 0.83
Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob Agents Chemother (2013) 0.82
Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob Agents Chemother (2005) 0.82
Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob Agents Chemother (2014) 0.81
Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep (2012) 0.80
Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans. Antimicrob Agents Chemother (2016) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep (2010) 8.16
Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep (2005) 6.45
Tuberculosis. Lancet (2003) 6.39
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
The effects of local review on informed consent documents from a multicenter clinical trials consortium. Control Clin Trials (2003) 3.30
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med (2009) 3.05
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 2.69
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med (2003) 2.56
Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med (2008) 2.55
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis (2009) 2.36
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis (2005) 2.34
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Voluntary medical male circumcision: translating research into the rapid expansion of services in Kenya, 2008-2011. PLoS Med (2011) 2.31
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis (2007) 2.28
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr (2015) 2.26
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med (2011) 2.17
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. Int J Tuberc Lung Dis (2014) 2.08
Voluntary medical male circumcision: strategies for meeting the human resource needs of scale-up in southern and eastern Africa. PLoS Med (2011) 2.08
Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care Settings. Sex Transm Dis (2006) 2.07
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04
Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS (2008) 2.02
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
Latent TB infection treatment acceptance and completion in the United States and Canada. Chest (2009) 1.97
Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med (2004) 1.96
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med (2009) 1.95
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med (2012) 1.94
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis (2006) 1.91
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Parental delay or refusal of vaccine doses, childhood vaccination coverage at 24 months of age, and the Health Belief Model. Public Health Rep (2011) 1.89
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med (2005) 1.85
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis (2005) 1.81
Genetic rescue of nonclassical ERα signaling normalizes energy balance in obese Erα-null mutant mice. J Clin Invest (2011) 1.81
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med (2007) 1.78
In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes. PLoS One (2012) 1.74
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis (2009) 1.72